



THE UNIVERSITY OF BRITISH COLUMBIA
Faculty of Pharmaceutical Sciences

YEAR IN REVIEW

2018

2019





2018
2019

I am delighted to present a year in review for the most significant accomplishments of the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC). From April 1, 2018 to June 30, 2019, the Faculty continued to demonstrate excellence in each of its four priority areas of focus: Education, Research, Practice, People and Place. The Faculty has also shown significant growth in its international reputation, rising nine spots in the 2019 QS World Rankings, and an expansion in its academic and research programs, community outreach initiatives, and human resource complement with a number of new faculty and staff positions. As we look to the year ahead, I have no doubt that we will continue to gain further momentum as we work to achieve the ambitious goals set out in our strategic plan (*Catalyst for Change: 2017-2022*). I look forward to reporting back to you at this time again next year, and take this opportunity to acknowledge the many and varied contributions of our amazing faculty, staff and students.

Sincerely,

Michael Coughtrie BSc(Hons) PhD FCAHS
Professor and Dean

#20 Worldwide #2 in Canada

UP 9 SPOTS

AT A GLANCE



250+ PUBLICATIONS



80 GRANTS



60 AWARDS



84 MEDIA HITS

EDUCATION

RESEARCH

PRACTICE

PEOPLE AND PLACE

STUDENTS



856 Entry-to-Practice PharmD
16 Flexible PharmD
24 MSc and 38 PhD
72 Canadian Pharmacy Practice Program and 3,073 registrants in 49 Continuing Education Programs



\$8M RESEARCH INCOME



40% INCREASE FROM 2017/2018

6

MICHAEL SMITH FOUNDATION FOR HEALTH RESEARCH SCHOLARS



PHARMACISTS CLINIC

211 Patients receiving care per month in 2018/19

12,550 Patients cared for since Clinic opened (Nov 12/13 - Jun 30/19)

64% Physician referrals

BC Ministry of Health announced funding for 50 clinical pharmacists in primary care teams around the province. The Pharmacists Clinic training and operational systems are being used in the developmental phase and evaluation is included - \$23 million over three years.



The First Nations Health Authority, BC First Nations communities and the UBC Pharmacists Clinic are collaborating on new ways to improve access to pharmacist services, patient care and drug therapy outcomes for people in local communities.

77 Total Faculty
709 Clinical Faculty
16 Honorary Faculty
76 Total Staff
17 Postdoctoral Research Fellows
5 Research Associates
112 Student Workers



435 NEW ALUMNI

6,682 TOTAL ALUMNI



Alumni, students, and community members gathered on Wednesday, March 13 to celebrate the 2019 UBC Faculty of Pharmaceutical Sciences Alumni Agent of Change Sarvajna Dwivedi, MSc'88, PhD'92, and Future Alumni Agent of Change Tamara Mihic, BSc(Pharm)'13, PharmD'16.

EXPERIENTIAL EDUCATION

919 Practice Educators
511 Practice Sites in BC



Graduate PharmD degree and BSc(Pharm) degree programs conclude.

First Entry-to-Practice PharmD cohort graduates.

New BPSc degree program received Senate approval.

Dr. Larry Lynd joins the Faculty's senior leadership team as new associate dean, research.

NanoMedicines Innovation Network (NMIN) awarded \$18.5 million in new funding from the Networks of Centres of Excellence (NCE).

NEWS HIGHLIGHTS

APR
2018

UBC Pharm Sci assistant professor Mohsen Sadatsafavi to receive New Investigator Research Award

UBC Faculty of Pharmaceutical Sciences assistant professor Mohsen Sadatsafavi received the 2018 Association of Faculties of Pharmacy of Canada (AFPC) New Investigator Research Award.

SEP
2018

Professor Larry Lynd inducted into the Canadian Academy of Health Sciences

Dr. Larry Lynd, professor and director of the Collaboration for Outcomes Research and Evaluation (CORE) at the University of British Columbia (UBC) Faculty of Pharmaceutical Sciences, was named a Fellow of the Canadian Academy of Health Sciences (CAHS) on September 13, 2018.

OCT
2018

"Smart medicines" and the future of drug delivery

Scientists are getting closer to delivering drugs more precisely to their target in the body, according to Professor Urs Häfeli, who leads the UBC-University of Copenhagen Lundbeck Foundation professorship. With \$1.9 million CAD funding from the Lundbeck Foundation, the five-year joint professorship and PhD program at UBC and the University of Copenhagen aims to combine Canada and Denmark's research strengths in the emerging fields of drug delivery and nanomedicines.

NOV
2018

UBC Pharm Sci Assistant Professor Receives Canada Research Chair in Oncology

Dr. Karla Williams, assistant professor at the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) has received a Canada Research Chair in Oncology. She is one of 187 new and renewed Canada Research Chairs at 49 institutions across the country, and one of 12 new chair holders at UBC.

DEC
2018

UBC Pharm Sci professor to join Canadian research team studying the progression of multiple sclerosis

The University of British Columbia (UBC) Faculty of Pharmaceutical Sciences professor and director of the Collaboration for Outcomes Research and Evaluation (CORE), Dr. Larry Lynd, is a co-lead of a multidisciplinary team of Canadian researchers chosen to lead a \$7+ million dollar study into the progression of multiple sclerosis (MS) across the country, and one of 12 new chair holders at UBC.

APR
2019

Network to bring together researchers from across Canada to further development of nanomedicines

The Faculty of Pharmaceutical Sciences is excited to be closely involved in the NanoMedicines Innovation Network (NMIN) which has today been awarded \$18.5 million in new funding from the Networks of Centres of Excellence (NCE), a federal program that promotes collaboration between scientists across Canada. This funding is matched by over \$22 million in additional funding from industry and other not-for-profit agencies.

MAY
2019

Steroids can reduce lung cancer risk in COPD patients

For many people with chronic obstructive pulmonary disease or COPD, a steroid inhaler is a daily necessity to keep their airways open and help them to breathe. Now, a new UBC analysis shows that these medicated devices may also reduce patients' risk of lung cancer by as much as 30 per cent. Study author: Dr. Larry Lynd.